Publications
273
Citations
2,698
Est. group size
~28
Recurring co-author estimate
Active years
20
Publishing since 2007
Shelley Orwick's work sits within cancer medicine, with a focus on blood cancers such as leukemia and on understanding how certain cancer drugs (multikinase inhibitors) cause skin-related side effects. Recent output centers on a single detailed study examining how these drugs are taken up by skin cells and trigger cell death, using supplementary data, tables, and figures rather than distinct standalone papers. This suggests a role supporting large collaborative research projects on drug toxicity and blood cancer treatments.
Publication counts were relatively steady (single digits to low teens per year) from 2017-2022, then spiked sharply in 2023 and 2025, likely reflecting a burst of associated supplementary materials from a small number of major papers rather than a steady stream of distinct publications.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Table S2 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Supplementary References from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Data from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Figure S2 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Figure S3 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Supplementary Figure Legends from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- FIgure S1 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Figure S4 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Table S1 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Figure S4 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Data from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Table S3 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Figure S3 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Table S3 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Table S2 from Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
2023
- Blood×33
- Leukemia×15
- Cancer Research×8
- Blood Advances×7
- Journal of Hematology & Oncology×3
- Daelynn R. Buelow
Medicine · The Ohio State University
- Jae Yoon Jeon
Medicine · The Ohio State University
- Ying Huang
Medicine · The Ohio State University
- Sharyn D. Baker
Medicine · The Ohio State University
- Kieran Sahasrabudhe
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile